Ghosh Arun K, Hsu Che-Sheng
J Org Chem. 2021 May 7;86(9):6351-6360. doi: 10.1021/acs.joc.1c00172. Epub 2021 Apr 19.
We describe here an enantioselective synthesis of (+)-EBC-23, a potent anticancer agent from the Australian rainforest. Our convergent synthesis features a [3+2] dipolar cycloaddition of an olefin-bearing 1,3- diol unit and an oxime segment containing 1,2- diol functionality as the key step. The segments were synthesized in a highly enantioselective manner using Noyori asymmetric hydrogenation of a β-keto ester and Sharpless asymmetric dihydroxylation of an α,β-unsaturated ester. Cycloaddition provided isoxazoline derivative which upon hydrogenolysis furnished the β-hydroxy ketone expediently. A one-pot, acid-catalyzed reaction removed the isopropylidene group, promoted spirocyclization, constructed the complex spiroketal lactone core, and furnished EBC-23 and its C11 epimer. The C11 epimer was also converted to EBC-23 by chemoselective oxidation and reduction sequence. The present synthesis provides convenient access to this family of natural products in an efficient manner.
我们在此描述了(+)-EBC-23的对映选择性合成,(+)-EBC-23是一种源自澳大利亚雨林的强效抗癌剂。我们的汇聚合成以带有烯烃的1,3-二醇单元与含有1,2-二醇官能团的肟片段的[3+2]偶极环加成反应为关键步骤。这些片段通过β-酮酯的野依不对称氢化反应和α,β-不饱和酯的夏普莱斯不对称双羟基化反应以高度对映选择性的方式合成。环加成反应生成异恶唑啉衍生物,该衍生物经氢解反应可方便地得到β-羟基酮。一锅法酸催化反应去除了亚异丙基,促进了螺环化反应,构建了复杂的螺环缩酮内酯核心,并得到了EBC-23及其C11差向异构体。C11差向异构体也通过化学选择性氧化和还原序列转化为EBC-23。本合成方法以高效的方式为该类天然产物提供了便利的获取途径。